A Study on analysis of contrasts and variation in SUV with the passage of uptake time in 18F-FDOPA Brain PET/CT
![]() |
Seo, Kang rok
(Department of Nuclear Medicine, Asan medical Center)
Lee, Jeong eun (Department of Nuclear Medicine, Asan medical Center) Ko, Hyun soo (Department of Nuclear Medicine, Asan medical Center) Ryu, Jae kwang (Department of Nuclear Medicine, Asan medical Center) Nam, Ki pyo (Department of Nuclear Medicine, Asan medical Center) |
1 |
Patronas NJ, Di Chiro G, Brooks RA, et al. Work in progress: [ |
2 | Di Chiro G, Oldfield E, Wright DC, et al. Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studies. AJR. 1988;150:189-197. DOI |
3 |
Doyle WK, Budinger TF, Valk PE, Levin VA, Gutin PH. Differentiation of cerebral radiation necrosis from tumor recurrence by [ |
4 | Wong TZ, van der Westhuizen GJ, Coleman RE. Positron emission tomography imaging of brain tumors. Neuroimaging Clin N Am. 2002;12:615-626. DOI |
5 | Olivero WC, Dulebohn SC, Lister JR. The use of PET in evaluating patients with primary brain tumors: Is it useful? J Neurol Neurosurg Psychiatry. 1995;58:250-252. DOI |
6 | Ricci PE, Karis JP, Heiserman JE, et al. Differentiaing recurrent tumor from radiation necrosis: time for re-evaluation of positron emission tomography? Am J Neuroradiol. 1998;19:407-413. |
7 | Delbeke D, Meyerowitz C, Lapidus RL, et al. Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET. Radiology. 1995;195:47-52. DOI |
8 | Padoma MV, Said S, Jacobs M, et al. Prediction of pathology and survival by FDG PET in gliomas. J Neurooncol. 2003;64:227-237. DOI |
9 | Ishiwata K, Kutota K, Murakami M, et al. Reevaluation of amino acid PET studies: Can the protein synthesis rates in brain and tumor tissues be measured in vivo? J Nucl Med. 1993;34:1936-1943. |
10 | Jager PL, Vaalburg W, Pruim J, et al. Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med. 2001;42:432-445. |
11 | Herholz K, Holzer T, Bauer B, et al. 11C-Methionine PET for differential diagnosis of low-grade gliomas. Neurology. 1998;50:1316-1322. DOI |
12 | Laverman P, Boerman OC, Corstens FHM, et al. Fluorinated amino acids for tumour imaging with positron emission tomography. Eur J Nucl Med. 2002;29:681-690. DOI |
13 | Wester HJ, Herz M, Weber W, et al. Synthesis and radiopharmacology of O-(2-[18F]fluoroethyl)-L-tyrosine for tumor imaging. J Nucl Med. 1999;40:205-212. |
14 | Weber WA, Wester HJ, Grosu AL, et al. O-(2-[18F] Fluoroethyl)-L-tyrosine and L-[methyl-11C]methionine uptake in brain tumours: initial results of a comparative study. Eur J Nucl Med. 2000;27:542-549. DOI |
15 |
Wei Chen, Daniel H.S S, Sibylle D, et al. |
16 | Pauleit D, Floeth F, Hamacher K, et al. O-(2-[18F] Fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain. 2005;128:678-687. DOI |
17 | Heiss WD, Wienhard K, Wagner R, et al. F-Dopa as an amino acid tracer to detect brain tumors. J Nucl Med. 1996;37:1180-1182. |
18 | Becherer A, Karanikas G, Szabo M, et al. Brain tumour imaging with PET: a comparison between [18F]fluorodopa and [11C]methionine. Eur J Nucl Med Mol Imaging. 2003;30:1561-1567. DOI |
![]() |